Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 21 03 2021
accepted: 12 05 2021
entrez: 2 8 2021
pubmed: 3 8 2021
medline: 3 11 2021
Statut: epublish

Résumé

Lymphomas are cancers deriving from lymphocytes, arising preferentially in secondary lymphoid organs, and represent the 6th cancer worldwide and the most frequent blood cancer. The majority of B cell Non-Hodgkin lymphomas (B-NHL) develop from germinal center (GC) experienced mature B cells. GCs are transient structures that form in lymphoid organs in response to antigen exposure of naive B cells, and where B cell receptor (BCR) affinity maturation occurs to promote B cell differentiation into memory B and plasma cells producing high-affinity antibodies. Genomic instability associated with the somatic hypermutation (SHM) and class-switch recombination (CSR) processes during GC transit enhance susceptibility to malignant transformation. Most B cell differentiation steps in the GC are at the origin of frequent B cell malignant entities, namely Follicular Lymphoma (FL) and GCB diffuse large B cell lymphomas (GCB-DLBCL). Over the past decade, large sequencing efforts have provided a great boost in the identification of candidate oncogenes and tumor suppressors involved in FL and DLBCL oncogenesis. Mouse models have been instrumental to accurately mimic

Identifiants

pubmed: 34335584
doi: 10.3389/fimmu.2021.683597
pmc: PMC8323519
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

683597

Informations de copyright

Copyright © 2021 Mossadegh-Keller, Brisou, Beyou, Nadel and Roulland.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Blood. 2020 Nov 12;136(20):2263-2274
pubmed: 32932517
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Nat Immunol. 2015 Mar;16(3):296-305
pubmed: 25642821
Blood Adv. 2018 Mar 27;2(6):703-714
pubmed: 29581109
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Immunity. 2013 May 23;38(5):918-29
pubmed: 23684984
Cell Rep. 2020 May 5;31(5):107522
pubmed: 32330423
Nat Med. 2016 Jun;22(6):632-40
pubmed: 27135738
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Cancer Cell. 2013 May 13;23(5):677-92
pubmed: 23680150
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9701-9706
pubmed: 28831000
Blood. 2012 Sep 13;120(11):2240-8
pubmed: 22740445
Cancer Cell. 2010 Dec 14;18(6):568-79
pubmed: 21156281
Blood. 2018 Dec 20;132(25):2687-2690
pubmed: 30401710
Nat Genet. 2016 Feb;48(2):183-8
pubmed: 26691987
Immunol Rev. 2019 May;289(1):158-172
pubmed: 30977196
Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):
pubmed: 32398289
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32603407
Nat Immunol. 2020 Jun;21(6):660-670
pubmed: 32341509
Cancer Discov. 2020 Mar;10(3):440-459
pubmed: 31915197
Immunity. 2017 Jun 20;46(6):1045-1058.e6
pubmed: 28636954
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
Leukemia. 2011 Sep;25(9):1484-93
pubmed: 21606958
Cell. 2020 Jul 23;182(2):297-316.e27
pubmed: 32619424
Immunol Rev. 2019 Mar;288(1):240-261
pubmed: 30874347
Nature. 2018 Aug;560(7718):387-391
pubmed: 29925955
Clin Cancer Res. 2016 Nov 1;22(21):5383-5393
pubmed: 27267853
Immunity. 2019 Aug 20;51(2):310-323.e7
pubmed: 31204070
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
J Exp Med. 2006 Oct 30;203(11):2425-31
pubmed: 17043145
Cell. 1989 Apr 7;57(1):79-88
pubmed: 2649247
Nature. 1985 Dec 12-18;318(6046):533-8
pubmed: 3906410
Mol Cell Biol. 2003 Jul;23(13):4559-72
pubmed: 12808097
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Cancer Cell. 2016 Apr 11;29(4):574-586
pubmed: 27070704
Nature. 2021 Jan;589(7841):299-305
pubmed: 33299181
Curr Opin Hematol. 2018 Jul;25(4):335-345
pubmed: 29746265
Nat Rev Immunol. 2015 Mar;15(3):172-84
pubmed: 25712152
Cancer Cell. 2012 Aug 14;22(2):167-79
pubmed: 22897848
Immunol Rev. 2012 May;247(1):172-83
pubmed: 22500840
Cancer Cell. 2016 Aug 8;30(2):197-213
pubmed: 27505670
PLoS Med. 2016 Dec 13;13(12):e1002197
pubmed: 27959929
Cell Stem Cell. 2017 Oct 5;21(4):547-555.e8
pubmed: 28985529
Nat Med. 2015 Oct;21(10):1190-8
pubmed: 26366712
Nat Rev Immunol. 2021 Apr;21(4):209-220
pubmed: 33024284
Front Immunol. 2019 Jan 11;9:3114
pubmed: 30687320
Nature. 2014 Dec 11;516(7530):254-8
pubmed: 25274307
Cancer Discov. 2020 Dec;10(12):1912-1933
pubmed: 32887696
Nat Metab. 2019 Aug;1(8):775-789
pubmed: 31579886
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Nat Immunol. 2012 Nov;13(11):1092-100
pubmed: 23001146
Nat Immunol. 2016 Jul;17(7):861-9
pubmed: 27158841
Nature. 2012 Oct 4;490(7418):116-20
pubmed: 22885699
Immunity. 2019 Sep 17;51(3):535-547.e9
pubmed: 31519498
Blood. 2019 Mar 7;133(10):1119-1129
pubmed: 30591526
Nat Immunol. 2015 Jun;16(6):653-62
pubmed: 25867473
Immunol Rev. 2019 Mar;288(1):214-239
pubmed: 30874354
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2989-94
pubmed: 22323599
Blood. 2013 Oct 31;122(18):3165-8
pubmed: 24052547
Cell. 2020 Jan 9;180(1):92-106.e11
pubmed: 31866068
Immunol Rev. 2019 Sep;291(1):190-213
pubmed: 31402495
Cancer Cell. 2018 Sep 10;34(3):453-465.e9
pubmed: 30205047
Cancer Discov. 2018 Dec;8(12):1632-1653
pubmed: 30274972
Curr Opin Hematol. 2015 Jul;22(4):388-96
pubmed: 26049761
Cell Rep. 2020 Nov 17;33(7):108403
pubmed: 33207194
Cell. 2016 Oct 6;167(2):405-418.e13
pubmed: 27693350
Biomaterials. 2019 Apr;198:27-36
pubmed: 30041943
J Immunol. 2007 Nov 1;179(9):6033-42
pubmed: 17947677
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Cancer Discov. 2017 Jan;7(1):38-53
pubmed: 27733359
Nat Rev Immunol. 2015 Mar;15(3):137-48
pubmed: 25656706
Oncogene. 1993 Jan;8(1):1-9
pubmed: 8423986
Cell. 2010 Apr 16;141(2):290-303
pubmed: 20381137
Cancer Discov. 2021 Jun;11(6):1468-1489
pubmed: 33541860
J Clin Invest. 2014 Dec;124(12):5337-51
pubmed: 25384217
Blood. 2017 May 11;129(19):2645-2656
pubmed: 28288979
Blood Cancer Discov. 2021 Jan;2(1):70-91
pubmed: 33447829
Leuk Lymphoma. 2020 Apr;61(4):788-798
pubmed: 31752573
Nat Rev Dis Primers. 2019 Dec 12;5(1):83
pubmed: 31831752
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25
pubmed: 25713363
Adv Hematol. 2012;2012:701704
pubmed: 22400032
Nat Immunol. 2018 Sep;19(9):1013-1024
pubmed: 30104629
Nature. 2011 Mar 10;471(7337):189-95
pubmed: 21390126
Cancer Cell. 2011 Jul 12;20(1):25-38
pubmed: 21723201
Cancer Cell. 2010 Dec 14;18(6):580-9
pubmed: 21156282
Immunol Rev. 2020 Jul;296(1):48-61
pubmed: 32412663
Nature. 2015 Mar 26;519(7544):477-81
pubmed: 25561175
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
Nat Cell Biol. 2017 Sep;19(9):1093-1104
pubmed: 28825697
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8661-5
pubmed: 1924327
Nat Immunol. 2020 Jun;21(6):649-659
pubmed: 32424359
Cell Rep. 2014 Jan 16;6(1):130-40
pubmed: 24388756
Cancer Cell. 2020 May 11;37(5):674-689.e12
pubmed: 32330455
Adv Immunol. 2010;105:193-210
pubmed: 20510734
Nat Genet. 2014 Feb;46(2):176-181
pubmed: 24362818
Nat Commun. 2017 Oct 12;8(1):877
pubmed: 29026085
Sci Immunol. 2021 Feb 12;6(56):
pubmed: 33579751
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659443
Nat Immunol. 2006 Jul;7(7):773-82
pubmed: 16767092
Blood. 2004 Mar 15;103(6):2276-83
pubmed: 14630790
Cold Spring Harb Perspect Med. 2020 Dec 1;10(12):
pubmed: 32014848
Cancer Cell. 2007 Sep;12(3):280-92
pubmed: 17785208
J Clin Invest. 2013 Dec;123(12):5009-22
pubmed: 24200695
Nat Genet. 2010 Feb;42(2):181-5
pubmed: 20081860
Cancer Cell. 2020 May 11;37(5):655-673.e11
pubmed: 32396861
Blood. 2016 Jun 2;127(22):2732-41
pubmed: 27048211
Nat Med. 2015 Oct;21(10):1199-208
pubmed: 26366710
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13447-54
pubmed: 26483459
Immunity. 2018 Feb 20;48(2):313-326.e5
pubmed: 29396161
Blood. 2014 Mar 6;123(10):1487-98
pubmed: 24435047
Nat Immunol. 2020 Sep;21(9):1082-1093
pubmed: 32601467
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7396-401
pubmed: 16651521
Adv Immunol. 2011;111:1-46
pubmed: 21970951
Nat Immunol. 2012 Nov;13(11):1083-91
pubmed: 23001145
Trends Mol Med. 2014 Jun;20(6):343-52
pubmed: 24698494
Cancer Discov. 2017 Mar;7(3):322-337
pubmed: 28069569
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33332554
Nat Immunol. 2009 Dec;10(12):1292-9
pubmed: 19855380
Curr Opin Immunol. 2017 Apr;45:31-36
pubmed: 28160624
Cancer Discov. 2019 Apr;9(4):546-563
pubmed: 30705065
Cancer Res. 2005 Feb 15;65(4):1306-15
pubmed: 15735016

Auteurs

Noushin Mossadegh-Keller (N)

Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.

Gabriel Brisou (G)

Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.
Department of Hematology, Institut Paoli-Calmettes, Marseille, France.

Alicia Beyou (A)

Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.

Bertrand Nadel (B)

Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.

Sandrine Roulland (S)

Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH